Transcenta Holding Limited
6628.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$345.22M
Close$
$-0.69
206.4% downside
Current Fair Value
206.4% downsideOvervalued by 206.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $345.22 Million |
|---|---|
| Enterprise Value | $479.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.48 |
| Beta | -0.47 |
| Outstanding Shares | 426,376,367 |
Return
| Return on Equity | -29.16% |
|---|---|
| Return on Assets | -18.09% |
| Return on Invested Capital | -23.04% |
Valuation & Multiples
| P/E Ratio | -1.82 |
|---|---|
| PEG | 4.72 |
| Price to Sales | - |
| Price to Book Ratio | 0.65 |
| Enterprise Value to Revenue | 16.93 |
| Enterprise Value to EBIT | -3.23 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$29.52 M
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
$62.79 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Transcenta Holding Limited
150 employees
CEO: Xueming Qian Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United Sta...